Objective: This study aimed to investigate the association between aspirin use and outcome indicators in patients combined with chronic obstructive pulmonary disease and heart failure (COPD-HF). Methods: Data from COPD-HF patients were extracted from the MIMIC-IV database. Propensity score matching (PSM) was employed to minimize confounding biases after multiple imputations of missing data. Baseline characteristics and outcomes were compared between the aspirin users group and the aspirin non-users group. Logistic regression, Cox proportional hazard (Cox) regression, Kaplan-Meier (KM) survival analysis and Restricted cubic splines (RCS) were used to explore the relationship between aspirin use and outcome indicators. Results: A total of 1753 COPD-HF patients were included. Among 1350 propensity score-matched patients, the distribution of different outcome indicators and multivariate logistic regression revealed that aspirin use was associated with lower in-hospital and 1-year mortality (p < 0.05). Both Cox regression and KM analyses confirmed that aspirin use significantly reduced in-hospital mortality, but there was no significant difference in 1-year mortality. Subgroup analysis showed that aspirin use notably decreased in-hospital mortality in females, whites, non-smokers, and non-drinkers. Cox regression showed that in-hospital and 1-year mortality were independent of aspirin dose. RCS showed that there was a linear relationship between aspirin use duration and in-hospital and 1-year mortality (non-linear p > 0.05). Conclusions: Aspirin use significantly reduces in-hospital mortality. Aspirin dosage is not associated with in-hospital mortality, while duration of use shows a linear correlation with mortality risk.